EUVIMEDEUVIMED entdecken
Kontrollierte klinische StudieOpen Access · CC BY 4.0

Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency

Matthias G Vossen, Felix Kartnig, Daniel Mrak, Elisabeth Simader, Karin Stiasny, Renate Kain, Thomas Perkmann, Helmuth Haslacher, Judith H Aberle, Leonhard X Heinz, Daniela Sieghart, Heinz Burgmann und 4 weitere

Wiener klinische Wochenschrift · 2024

DOI: 10.1007/s00508-024-02459-6 ↗

Kurz gefasst

Kontrollierte klinische Studie in der Zeitschrift Wiener klinische Wochenschrift, 2024. Verfasst von Matthias G Vossen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Immunity, Humoral, Immunity, Cellular. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Impaired immune response to COVID-19 (coronavirus disease 2019) vaccination has been reported in patients with inborn errors of immunity (IEI). Repetitive vaccinations are recommended for this vulnerable group. Due to the high diversity within IEI patients, additional safety and immunogenicity data are needed to better understand these aspects especially in less common immunodeficiency syndromes. In this prospective open-label clinical trial, we assessed the humoral immune response and the T‑cell response in patients with IEI or severe MBL (mannose-binding lectin) deficiency (IEI/MBLdef) after three vaccinations. A total of 16 patients and 16 matched healthy controls (HC) with suboptimal humoral response defined by anti-SARS-CoV‑2 RBD (severe acute respiratory syndrome coronavirus type 2 receptor binding domain) antibodies below 1500 BAU/ml (binding antibody units per ml) after the second COVID-19 vaccination were enrolled in this study and qualified for a third mRNA vaccine dose. After 4 weeks following vaccination, 100% of HC and 75% of IEI/MBLdef patients exhibited anti-SARS-CoV‑2 RBD antibodies > 1500 BAU/ml, although the difference was not statistically significant (75% vs. 100%; p = 0.109). Although post-vaccination IEI/MBLdef patients demonstrated significantly increased anti-SARS-CoV‑2 RBD antibodies and neutralizing antibodies compared to baseline, these responses were significantly lower in IEI/MBLdef patients compared to HCs. Notably, the third vaccination augmented the cellular immune response to both wild-type and omicron peptide stimulation. No serious adverse events were reported within the 4‑week follow-up period and, importantly, vaccination had little to no effect on the long-term disease activity and fatigue. This trial strongly supports the recommendation of repeated COVID-19 vaccinations for patients suffering from immunodeficiencies, especially when they exhibit an initially limited response to the vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19Immunity, HumoralImmunity, CellularHumansMaleFemaleProspective StudiesAdultSARS-CoV-2Middle AgedAntibodies, ViralImmunologic Deficiency SyndromesMannose-Binding LectinPrimary Immunodeficiency DiseasesImmunization, SecondaryMetabolism, Inborn Errors

Stichwörter der Autor:innen

Common variable immunodeficiencyHypogammaglobulinemiaImmunosuppressionMannose-binding lectinPrimary immunodeficiency disorder

Substanzen

COVID-19 VaccinesAntibodies, ViralMannose-Binding Lectin

Autor:innen und Institutionen

  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Comprehensive Center for Infection Medicine, Medical University of Vienna, Austria (CCIM), Vienna, Austria.
  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.
  • Center for Virology, Medical University of Vienna, Vienna, Austria.
  • Medical University of Vienna, Clinical Institute for Pathology, Vienna, Austria.

Förderung

  • Medical University of Vienna

Zitieren

APA

Vossen, M. G., Kartnig, F., Mrak, D., Simader, E., Stiasny, K., Kain, R., Perkmann, T., Haslacher, H., Aberle, J. H., Heinz, L. X., Sieghart, D., Burgmann, H., Aletaha, D., Scheinecker, C., Bonelli, M., & Göschl, L. (2024). Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02459-6

Vancouver

Vossen MG, Kartnig F, Mrak D, Simader E, Stiasny K, Kain R, et al. Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency. Wiener klinische Wochenschrift. 2024. doi:10.1007/s00508-024-02459-6

BibTeX
@article{Vossen2024,
  author = {Vossen, Matthias G and Kartnig, Felix and Mrak, Daniel and Simader, Elisabeth and Stiasny, Karin and Kain, Renate and Perkmann, Thomas and Haslacher, Helmuth and Aberle, Judith H and Heinz, Leonhard X and Sieghart, Daniela and Burgmann, Heinz and Aletaha, Daniel and Scheinecker, Clemens and Bonelli, Michael and Göschl, Lisa},
  title = {Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency},
  journal = {Wiener klinische Wochenschrift},
  year = {2024},
  doi = {10.1007/s00508-024-02459-6}
}
Kostenlos starten →